Literature DB >> 28605929

Tissue necrosis following extravasation of acyclovir in an adolescent: A case report.

Charalambos Neocleous1, Eleni Andonopoulou2, Alkistis Adramerina2, Antigoni Pegkou2, Olga Savelieva2, Petroula Georgiadou2, Ioannis Drikos2.   

Abstract

OBJECTIVE: Extravasation of intravenously infused vesicant solutions is a common problem in medical practice, which can lead to severe and progressive tissue dysfunction, ranging from persistent tissue oedema and fibrosis to delayed tissue necrosis. Acyclovir is a known vesicant medication administrated in paediatric patients, which appears to irritate venous and soft tissue if extravasated. CASE REPORT: We present the first case involving the extravasation of intravenously infused acyclovir in a female adolescent patient, which caused tissue necrosis and left behind a residual scar lesion. Nursing and medical staff should be aware of the potential dermatological side effects of intravenously infused acyclovir and other medications, even a long time after infusion, and the possible lack of initial local symptoms and signs.
CONCLUSION: Early recognition of extravasation and prompt management are critical in preventing further morbidity, and optimizing outcomes.
Copyright © 2017 by Academy of Sciences and Arts of Bosnia and Herzegovina.

Entities:  

Keywords:  Acyclovir; Extravasation; Tissue necrosis

Mesh:

Substances:

Year:  2017        PMID: 28605929     DOI: 10.5644/ama2006-124.187

Source DB:  PubMed          Journal:  Acta Med Acad        ISSN: 1840-1848


  2 in total

Review 1.  Upper limb extravasation of cytotoxic drugs: results of the saline washout technique in children.

Authors:  Virginie Mas; Anne Laure Simon; Ana Presedo; Cindy Mallet; Brice Ilharreborde; Pascal Jehanno
Journal:  J Child Orthop       Date:  2020-06-01       Impact factor: 1.548

2.  Intraosseous infusion of acyclovir in a neonate.

Authors:  Saverio De Marca; Matteo Calafatti; Luciana Romaniello; Simona Pesce; Rosa Lapolla; Camilla Gizzi
Journal:  Ital J Pediatr       Date:  2022-09-06       Impact factor: 3.288

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.